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Neural tissue exposure to valproic acid (VPA) increases several pro-survival phospho-proteins that can be
used as biomarkers for indicating a beneﬁcial drug response (pAktSer473, pGSK3bSer9, pErk1/2Thr202/Tyr204).
Unfortunately, targeting VPA to neural tissue is a problem due to severe asymmetrical distribution,
wherein the drug tends to remain in peripheral blood rather than localizing within the brain. Intrace-
rebral delivery of an amide-linked VPAePEG conjugate could address these issues by enhancing reten-
tion and promoting cerebro-global increases in pro-survival phospho-proteins. It is necessary to assay for
the retained bioactivity of a PEGylated valproic acid molecule, along with locating an intracranial cannula
placement that optimizes the increase of a known downstream biomarker for chronic VPA exposure.
Here we show an acute injection of VPAePEG conjugate within brain tissue increased virtually all of the
assayed phospho-proteins, including well-known pro-survival factors. In contrast, an acute injection of
VPA expectedly decreased signaling throughout the hour. Needle penetration into whole brain tissue is
the intentional cause of trauma in this procedure. The trauma to brain tissue was observed to overcome
known phospho-protein increases for unmodiﬁed VPA in the injected solution, while VPAePEG conju-
gate appeared to induce signiﬁcant increases in pro-survival phospho-proteins, despite the procedural
trauma.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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Valproic acid (VPA) is a simple 8-carbon carboxylic acid that
has been shown to increase pro-survival biomarkers in cell cul-
ture, peripheral administration and chronic intracerebral delivery
(1). Several of the increased biomarkers are the phospho-
proteins, pAktSer473, pGSK3bSer9 and pErk1/2Thr202/Tyr204; with
total protein increases seen in factors such as glial-derived neu-
rotrophic factor (GDNF) and brain-derived neurotrophic factor
(BDNF) (2). While neurologically beneﬁcial, peripheral adminis-
tration of VPA usually carries unwanted side effects on non-
targeted organs, which can lead to life-threatening complica-
tions (1). Intracerebral delivery of VPA could circumvent endan-
gering peripheral organs by releasing drug directly into target
tissue at a signiﬁcantly lower concentration, while still enhancing
the protection of neurological function (1,3,4). Agents capable of
increasing survival signaling events involving Akt and Erk, like
VPA, have been shown to confer protection during various insults,
such as chemical exposure, traumatic brain injury (TBI) andnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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deacetylase inhibitor (HDI), which is a drug class that has been
identiﬁed to promote survival in neurodegenerative disease
models (11e13). Conversely, while VPA has many examples of
preventing cell death, it has been reported to increase apoptosis
and immunogenicity in tumor cells (14).
In a previous paper (1) we postulated the use of intracerebral
VPA administration, but the application is limited due to the drug's
poor blood-to-brain ratio (15e19). Cornford et al (15) reported the
rat brain-to-blood efﬂux of radiolabeled VPA from CSF to be faster
than that of water and such a change was observable within 4 min.
Furthermore, Kakee et al (17) intracerebrally injected Sprague
Dawley (SD) rats with 25mMVPA and found an 89.1% removal after
5 min, which was not signiﬁcantly different from their 100%
clearance control. This perhaps explains how patients taking pe-
ripheral VPA have been reported to show wide variations in con-
centration ranging from 39 mM to 185 mM in brain tissue and
18 mMe262 mM in cerebrospinal ﬂuid (CSF; (20)). The main cause
for this asymmetrical distribution is still unknown, but VPA appears
not to be transported by Pgp, MRP1 or MRP2 at the bloodebrain
barrier (BBB)/blood-CSF barrier (BCSFB; (21)). Such evidence for
carrier mediation is provided by Kakee et al (17), who reported VPA
clearance to signiﬁcantly decrease to 40.2% after 5 min upon
intracerebrally injecting 50 mM VPA in an attempt to overload the
unknown mechanism.
Combining intracerebral infusion with a simple amide-linked
VPAePEG conjugate molecule could address this rapid ‘leak’
issue by increasing intracerebral drug retention, rather than it
exiting into peripheral circulation shortly after entering the brain.
Borrowing from a prodrug design concept, to ‘lock-in’ the thera-
peutic agent, we would enhance the size and water solubility
with a biocompatible poly-ethylene glycol (PEG) molecule to
promote brain compartmentalization (22,23). We would also
exploit the rapid clearance of unmodiﬁed VPA from the cerebral
compartment to test for successful enhancement of tissue
retention and preserved bioactivity by assaying for the known
downstream biomarkers of VPA exposure within whole brain
tissue.
In the current study, we assayed for differential phospho-
protein levels in brain tissue after an acute injection of VPA or
VPAePEG conjugate in a whole animal model. This helped us to
verify injection site retention and preserved bioactivity of the
conjugate versus unmodiﬁed drug performance. In addition, three
separate groups of rats were chronically infused for 25 days at a
different location for each group to help address infusion site
importance in biomarker elevation (BDNF) and long-term exposure
to the drug solution (sagittal ﬁssure, lateral ventricle, caudate pu-
tamen tissue). We also ran behavioral paradigms on the chronically
infused rats to determine if there were any overt behavioral per-
turbations brought on by the conjugate.2. Material and methods
2.1. Animals
Adult male Sprague Dawley rats (Harlan SD, Indianapolis ID)
were housed in pairs in shoe box cages with aspen chip bedding,
prior to experiments, under constant temperature (21 C, ±1 C)
and 12 h lighting (lights on from 6 a.m. to 6 p.m.). Rats were given
access to water and rodent chow (Harlan Teklad; Indianapolis, IN)
ad libitum. Procedures have been approved by the Institutional
Animal Care and Use Committee (IACUC, Veterans Affairs Medical
Center, Eastern Colorado Healthcare System) and follow American
Association for Laboratory Animal Science (AALAS) guidelines.2.2. Conjugation of valproic acid with tri-branched poly-(ethylene
glycol) molecule
Widely used zero-length crosslinking agents were reacted to
form a stable amide bond between a tri-branched PEG and VPA
molecule (2.3 kDa). Both molecules have single parking areas,
creating an optimal conjugation by allowing only one VPAePEG
conjugate species to form. For the reaction mix, amino-dPEG4-(m-
dPEG12)3 (Quanta BioDesign Ltd., 10400; Powell, OH) was added to
0.1 M MES buffer (pH 5; 2-(N-morpholino)ethanesulfonic acid),
rocked at room temperature in a glass vial until completely dis-
solved, then ﬁlter sterilized into a new glass vial (National Scien-
tiﬁc, B7800e3; Rockwood, TN). Each component was slowly added
dropwise to the reaction vial while being ﬁlter sterilized (0.2 mm
pore; EMD Millipore, SLGV004SL; Billerica, MA): valproic acid,
sulfo-NHS (sulfo-hydroxysuccinimide) and EDC (1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide). The ﬁnal reaction mixture
was wrapped in foil and gently rocked at 4 C for 4 h. The reacted
mixture was then glass pipetted into a dialysis cassette with a
molecular weight cutoff of 2 kDa (Pierce/Thermo Scientiﬁc, 87718;
Rockford, IL). Dialysis series occurred in a glass beaker with stirring
bar: 12 h in 2.3 L of PBS (phosphate buffered saline; 4 C; pH 7.4),
then three more exchanges of buffer at room temperature (2 h each
in 2.3 L). A glass syringe was then used to remove the solution,
wrapped in foil, and stored at 4 C. All glass andmetal utensils were
washed four times with Optima LC/MSwater (Fisher Chemical,W6-
500; Kalamazoo, MI) and Optima LC/MS methanol (Fisher Chemi-
cal, A456-500; Kalamazoo, MI) before use.
2.3. Acute intracranial injection surgery
Rats (275e300 g) were placed in a stereotaxic instrument
(Model 900, KOPF Instruments; Tujunga, CA) while anesthetized
under a vaporized isoﬂurane and oxygen mix (901807, Mobile
Laboratory Animal Anesthesia System, VetEquip Inc.; Pleasanton,
CA). The scalp was incised and a burr hole opened at coordinates:
[þ1mm anterior to bregma;þ2.6mm lateral tomidline]. Reference
coordinates and outline image used from Paxinos andWatson (1). A
25 gauge, 5/800 needle attached to a 1 ml syringe loaded with 100 ml
of 3 mM PEG/VPAwas slowly inserted into the burr hole and pulled
back to create a pocket (syringe attached to stereotax arm). The
solution was then injected over the course of 2.5 min to clear
contaminating blood/bone and deposit drug within the pocket
(allowed to backﬁll while slowly retracting needle). Approximately
5 ml of solution remained within the pocket after the backﬁlling
procedure was completed and clearing solution was absorbed with
sterile surgical spears (18105-01, Fine Science Tools; Foster City,
CA). After injection, the rat was kept under anesthesia until sample
collection (Fig. 1A).
2.4. Implant surgery
Rats (275e300 g) were anesthetized as described above. The
groups were stereotaxically implanted with a cannula (Brain Infu-
sion Kit 1, ALZET, Durect; Cupertino, CA) at one of the following
coordinates: [þ1 mm anterior to bregma; þ2.6 mm lateral to
midline and; 4.0 mm ventral to skull; right CPu tissue], [þ1 mm
anterior to bregma;þ1.3 mm lateral tomidline and; 4.0mmventral
to skull; right lateral ventricle], [þ1 mm anterior to bregma; 0 mm
lateral to midline and; 2.0 mm ventral to skull; mid sagittal ﬁssure;
spacers added to position above corpus callosum]. Reference co-
ordinates and outline image used from Paxinos andWatson (1). The
cannula was attached by Micro-Renathane tubing (MRE040,
Braintree Scientiﬁc; Braintree, MA) to an osmotic minipump
(Model 2004, 0.25 ml/h, ALZET, Durect; Cupertino, CA) loaded with
Fig. 1. Acute/chronic administration sites, biopsy locations and signaling pathways for assayed protein phospho-forms. Red dot in axial view indicates injection site while sagittal
view shows the biopsy needle pathway (A). Coronal view displays needle position in red while yellow-black pattern indicates needle retraction before drug release (A). Signaling
diagram displays phosphorylation sites on proteins of interest when brain tissue is exposed to VPA/VPAePEG conjugate (B). Red lines in coronal images represent cannula
placement locations for the chronically implanted rat groups (C). Axial view indicates the biopsy location for each cannula placement (red dot) and locations of biopsies taken from
all groups to assay for biomarkers representing drug penetrance (black dashes þ red dot) (C).
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taken to guarantee no air bubbles were trapped in tubing (slow
backﬁlling) since our experience suggests that trapped air de-
creases pump rate. The cannula was secured to the skull with
stainless steel screws and acrylic cement. After tracking the tubing
beneath the neck skin, the osmotic minipump was inserted into a
subcutaneous pocket at shoulder level and the incision was closed
with wound clips. A prophylactic injection of enroﬂoxacin (20 mg/
kg; Baytril; BAYER HealthCare Inc.; Leverkusen, Germany) was
administered at the end of the surgical procedure (Fig. 1C).
2.5. In vivo behavioral studies
Rats implanted with osmotic minipumps for chronic infusion
were allowed to recover for 14 days prior to behavioral testing.
Behavioral testing was performed in a counterbalanced design to
eliminate any potential order-of-testing effects. On the 15th day,
half of the rats in each group were tested in the elevated plus (EP)
maze, while the other half was tested in the open ﬁeld (OF) maze.
On day 22, the groups were reversed. Further experimental details
for behavioral studies can be found in Bates et al (1).
2.6. Tissue preparations
After 25 days, chronically implanted groups were anesthetized
with isoﬂurane inhalant anesthesia (3% in oxygen; Webster Veter-
inary; Sterling, MA) and perfused transcardially with 100ml of 0.9%
NaCl (Ricca Chemical, 7210e1; Arlington. TX) followed by 200ml of
buffered 10% formaldehyde (Fisher Chemical, SF 10 0e4; Kalama-
zoo, MI). Brains were then excised and biopsied with a 2 mm
diameter punch needle.
2.7. Sample lysate preparation
For each rat, a time point of 30 or 60 min was allowed to elapse
after an acute injection, followed by brain tissue removal using a
2 mm diameter biopsy needle (Braintree Scientiﬁc, MTP-33 31C;
Braintree, MA) and sacriﬁcing by decapitation. Biopsied tissue was
placed in a 2 ml Potter-Elvehjem tissue homogenizer with 400 ml of
2% SDS, 200 mM DTT, 20 mM TriseHCl (pH 6.5), phosphataseinhibitors (SigmaeAldrich, P2850, P5726; St. Louis, MO), 3 Pro-
tease Arrest (Calbiochem/EMD, 539124; Gibbstown, NJ) and ho-
mogenized immediately after extraction. 50 ml of lithium dodecyl
sulfate (LDS) buffer (Invitrogen; NP0008; Carlsbad, California) was
added to all samples, heated at 70 C for 15 min, then stored
at 20 C in a CoolRack M90 (BioCision, BCS-117; Mill Valley, CA)
until used in Western blot studies. Further experimental details for
lysing samples can be found in Bates et al (1).2.8. Western immunoblotting
The speciﬁc primary antibodies employed in this study were
from Cell Signaling Technology (Boston, MA) and diluted
1:1000e2000 unless noted otherwise: p85/55 PI3K Tyr458/Tyr199 pAb
(rabbit; 4228), PDK1 Ser241 mAb (rabbit; 3438), MEK1/2 Ser217/Ser221
mAb (rabbit; 9154), amyloid precursor protein (APP) pAb (rabbit;
2452), Akt mAb (mouse; 2920), p44/42 MAPK (Erk1/2) mAb (rab-
bit; 4695), GAP43 pAb (rabbit; 5307), GSK3bSer9 mAb (rabbit;
9323), p44/42 MAPK (Erk1/2)Thr202/Tyr204 mAb (rabbit; 4370),
AktSer473 mAb (rabbit; 4060), CREBSer133 mAb (rabbit; 9198),
AktThr308 mAb (rabbit; 2965), b-actin mAb (mouse; 3700), b3-
tubulin mAb (mouse; 4466), cJunSer73 mAb (rabbit; 3270), MAP-
KAPKThr334 mAb (rabbit; 3007), BADSer136 mAb (rabbit; 4366),
FOXO1Thr24 pAb (rabbit; 9464), FOXO1Ser256 pAb (rabbit; 9461),
MDM2Ser166 pAb (rabbit; 3521), brain derived neurotrophic factor
(BDNF) mAb (rabbit; Abcam, ab108319; Cambridge, MA). The
ordinate of each blot is the arbitrary band intensity for experi-
mental groups divided by loading control band intensity (b-actin;
AKT, Erk1/2, b3-tubulin used for further loading control validation).
Fold change values less than one are reported as the negative in-
verse of the fold change. Further experimental details for Western
blot can be found in Bates et al (1).2.9. Statistics and ﬁgures
Graphs, one-way analysis of variance (ANOVA) and repeated-
measures ANOVA, with HolmeSidak multiple comparison a pos-
teriori analyses (where appropriate), were performed using Sig-
maPlot version 13 for Windows (Systat Software Inc; San Jose, CA).
Table 1
Repeated-measures ANOVA results for open ﬁeld and elevated plus paradigms.
Paradigm Variable Region F(3,20) p
Open ﬁeld Percent time in region Outer 1.343 0.298
Middle 1.362 0.292
Center 1.050 0.399
Distance traveled in region Outer 0.858 0.484
Middle 2.024 0.154
Center 1.065 0.393
Elevated plus Percent time in arm Closed 0.622 0.612
Open 0.389 0.763
Center 0.477 0.703
Distance traveled in arm Closed 0.613 0.617
Open 1.981 0.160
Center 0.417 0.744
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3.1. Immunochemical results for brain tissue lysates from acute
intracerebral injection of VPA, PEG or VPAePEG conjugate
Rats were administered either VPA or VPAePEG conjugate via
an acute intracerebral injection and 30e60 min allowed to elapse
before biopsying to assay for multiple phospho-proteins
(Fig. 1A,B). VPAePEG conjugate samples from the acute injection
displayed signiﬁcant increases in pAktSer473, pGSK3bSer9, and
pErk1/2Thr202/Tyr204, while VPA samples displayed signiﬁcant de-
creases in pAktSer473 for both time points (Fig. 2A; Table 2). pErk1/
2Thr202/Tyr204 did not display a signiﬁcant change in VPA samples
for either time point, while pGSK3bSer9 signiﬁcantly decreased at
60 min (Fig. 2A; Table 2). pCREBSer133, p-mTORSer2448 and pFOX-
O1Ser256 all displayed signiﬁcant increases within the 30e60 min
period for VPAePEG conjugate treated samples; pMAPKAPKThr334
attained signiﬁcance only at the 60 min time point and p-
mTORSer2481 at 30 min (Fig. 2B1; Table 2). VPA samples signiﬁ-
cantly decreased at 30 min for pCREBSer133, pFOXO1Thr24, and p-
mTORSer2448 while at 60 min all four phospho-proteins attainedFig. 2. Immunochemical results for the acute intracerebral injection of VPA or VPAePEG con
injection of the conjugate while non-modiﬁed VPA injections displayed signiﬁcant decrea
decrease after the hour (A). The ordinate of each blot is the fold change intensity from un
control validation). Fold change values less than one are reported as the negative inverse osigniﬁcance (p-mTORSer2481 only at 60 min) (Fig. 2B1; Table 2).
pPDK1Ser241, pPI3KTyr458, pMEK1/2Ser217/Ser221, MDM2Ser166
(VPAePEG conjugate samples) and pBADSer136, pMDM2Ser166 (VPA
samples) all signiﬁcantly increased for both time points while
pPI3KTyr458 fell below signiﬁcance at 60 min (VPA samples)jugate. Pro-survival phospho-proteins displayed signiﬁcant increases 30e60 min after
ses (AeB2). Brain tissue exposure to the PEG-only component displayed a 3.4 fold
treated control after normalization (b-actin; AKT, Erk1/2, b3-tubulin used for loading
f the fold change; Table 2 for descriptive statistics; n ¼ 6 (AeB2); (*p < 0.05).
Table 2
Acute intracerebral administration samples. ANOVA results for Western blot studies.
Figure Drug F (2, 15) Untreated
vs. 30 min
p
Untreated
vs. 60 min
p
30 min
vs. 60 min
p
Fold change
control vs. 30 min
Fold change
control vs. 60 min
Fig. 2.
Untreated
Std err
Fig. 2.
30 min
Std err
Fig. 2.
60 min
Std err
Fig. 2A VPAePEG 48.38 0.027* <0.001* <0.001* 2.02 4.96 0.220 0.250 0.388
pAktSer473 VPA 36.61 <0.001* <0.001* 0.121 17.89 4.04 0.115 4.40 1.34
Fig. 2A VPAePEG 35.45 <0.001* <0.001* 0.005* 4.48 6.79 0.156 0.608 0.570
pGSK3bSer9 VPA 19.75 0.184 <0.001* <0.001* n.s. 6.28 0.136 0.150 1.38
Fig. 2A VPAePEG 17.14 0.334 <0.001* <0.001* n.s. 2.84 0.059 0.328 0.236
pErk1/2Thr202/Tyr204 VPA 1.481 0.447 0.286 0.595 n.s. n.s. 0.070 0.080 0.028
Fig. 2B1 VPAePEG 39.61 <0.001* 0.424 <0.001* 1.83 n.s. 0.035 0.108 0.046
p-mTORSer2481 VPA 8.632 0.062 0.003* 0.097 n.s. 1.65 0.079 0.081 0.182
Fig. 2B1 VPAePEG 15.36 0.094 <0.001* 0.005* n.s. 5.06 0.276 0.743 0.445
pMAPKAPK-2Thr334 VPA 1.355 0.320 0.635 0.453 n.s. n.s.
Fig. 2B1 VPAePEG 21.79 <0.001* <0.001* 0.557 1.87 1.78 0.060 0.108 0.117
p-mTORSer2448 VPA 19.24 <0.001* 0.005* 0.023* 4.14 1.80 0.118 0.524 0.284
Fig. 2B1 VPAePEG 22.66 <0.001* <0.001* 0.056 1.84 2.22 0.116 0.147 0.124
pCREBSer133 VPA 7.804 0.005* 0.030* 0.288 1.61 1.38 0.106 0.140 0.022
Fig. 2B1 VPAePEG 5.648 0.063 0.389 0.016* n.s. n.s.
pFOXO1Thr24 VPA 10.21 0.003* 0.004* 0.822 2.0 1.89 0.103 0.304 0.279
Fig. 2B1 VPAePEG 12.41 0.002* 0.001* 0.862 1.70 1.67 0.153 0.091 0.065
pFOXO1Ser256 VPA 0.010 0.949 0.996 0.999 n.s. n.s.
Fig. 2B2 VPAePEG 2.385 0.138 0.473 0.325 n.s. n.s.
pBADSer136 VPA 9.668 0.016* 0.002* 0.237 2.01 2.43 0.115 0.367 0.200
Fig. 2B2 VPAePEG 49.34 <0.001* <0.001* 0.999 1.64 1.64 0.060 0.035 0.054
pMDM2Ser166 VPA 30.02 <0.001* <0.001* 0.766 1.64 1.67 0.084 0.056 0.060
Fig. 2B2 VPAePEG 21.06 <0.001* <0.001* 0.553 2.12 2.25 0.115 0.220 0.068
pPI3KTyr458 VPA 6.075 0.011* 0.094 0.214 2.30 n.s. 0.140 0.395 0.194
Fig. 2B2 VPAePEG 128.7 <0.001* <0.001* <0.001* 2.42 3.75 0.150 0.096 0.107
pPDK1Ser241 VPA 3.232 0.713 0.126 0.093 n.s. n.s.
Fig. 2B2 VPAePEG 37.48 <0.001* <0.001* 0.062 1.82 2.09 0.047 0.144 0.044
pMEK1/2Ser217/Ser221 VPA 5.048 0.025* 0.066 0.497 1.65 n.s. 0.125 0.184 0.147
Fig. 3A VPAePEG
Amyloid 110e140 kDa 5.063 0.035* 0.809 0.038* 1.38 n.s.
Precursor 45 kDa 5.162 0.039* 0.749 0.031* 1.42 n.s.
Protein VPA
(APP) 110e140 kDa 11.75 0.002* 0.003* 0.666 1.60 1.58
45 kDa 24.98 0.002* <0.001* 0.013* 1.54 1.97
Fig. 3B VPAePEG
Brain 32/28 kDa 1.134 0.816 0.453 0.449 n.s. n.s.
Derived 18/14 kDa 4.788 0.048* 0.950 0.036* 2.16 n.s.
Neurotro. VPA
Factor 32/28 kDa 58.77 <0.001* <0.001* 0.051 3.93 4.69
(BDNF) 18/14 kDa 44.46 <0.001* <0.001* 0.051 3.89 4.77
Fig. 3C VPAePEG 68.96 <0.001* <0.001* <0.001* 4.28 2.92
GAP-43 VPA 144.9 <0.001* <0.001* 0.300 15.44 16.54
Fig. 3D VPAePEG 0.681 0.611 0.710 0.704 n.s. n.s.
p-cJunSer73 VPA 31.64 <0.001* <0.001* 0.034* 4.27 3.29
Fig.Sup.1 VPAePEG 1.954 0.502 0.389 0.188 n.s. n.s.
pAktThr308 VPA 3.373 0.646 0.129 0.079 n.s. n.s.
*p < 0.05.
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signiﬁcantly at 30 min for the VPA samples (Fig. 2B2; Table 2).
pAktThr308 was not found to signiﬁcantly change for either drug
conﬁguration (S1, Supplemental Fig. 1; Table 2). The PEG-only
component was exposed to brain tissue to assess for an Akt pro-
survival effect, but only a 3.4 fold decrease could be detected
after 60 min (Fig. 2A). Western blot scan images can be found in
Supplemental Fig. 1 (S1; VPAePEG conjugate injected) and
Supplemental Fig. 2 (S2; VPA-only injected).
APP (110e140 kDa/45 kDa bands) were found to signiﬁcantly
increase at 30 min and then return to near baseline by 60 min for
the VPAePEG conjugate treated samples while VPA samples never
returned to baseline (Fig. 3A; Table 2). Pro-BDNF (32/28 kDa bands)
didn't change for either time point while mature-BDNF (18/14 kDa
bands) increased at 30 min for the VPAePEG conjugate samples
(Fig. 3B; Table 2). GAP-43 increased signiﬁcantly for both drug
conﬁgurations time points after injection while only p-cJunSer73
increased in VPA samples (Fig. 3C,D; Table 2).3.2. Immunochemical results for brain tissue lysates from chronic
intracerebral infusion of VPAePEG conjugate for 25 days
Rat groups were chronically administered VPAePEG conjugate
for 25 days in several cerebral locations (Fig. 1C; control, sagittal
ﬁssure, lateral ventricle, caudate putamen tissue). The pro- and
mature form of BDNF were signiﬁcantly increased within tissue at
the sagittal ﬁssure release site but did not show any change for the
posterior sample site (Fig. 1C, black dashes þ red dot; Fig. 3E,F;
n ¼ 6).
3.3. Behavior of chronically administered rats in elevated plus and
open ﬁeld maze
Rats receiving chronic administration of VPAePEG conjugate to
speciﬁc brain regions (Fig. 1C; control, sagittal ﬁssure, lateral
ventricle, caudate putamen tissue) were tested in both the Elevated
Plus (EP) and Open Field (OF) mazes to determine if there were any
Fig. 3. Immunochemical results of VPA and VPAePEG conjugate samples showing changes in protein distribution after an acute intracerebral injection. Several proteins signiﬁcantly
changed in their distribution within the needle-punctured area while others displayed no alteration or returned to baseline within the hour. Amyloid precursor protein (APP)
increased after 30 min in the VPAePEG conjugate samples, followed by a signiﬁcant decrease to baseline levels after 60 min (A). In contrast, VPA-treated samples did not decrease
after 60 min but maintained an elevated level (A). Brain derived neurotrophic factor (BDNF; pro-/mature) also displayed an elevated level for 30e60 min after VPA treatment while
VPAePEG conjugate samples showed only an increase in the 18/14 kDa bands (mature BDNF) at 30 min (B). Growth cone associated protein (GAP-43) was observed to increase for
both treated groups over the course of 60 min; VPA injection group displayed a greater fold increase than that of the VPAePEG conjugate group (C). p-cJunSer73 signiﬁcantly
increased in VPA-injected samples (D). Biopsy location posterior to the 3 mM VPAePEG conjugate release sites displayed no signiﬁcant change in BDNF (pro-/mature) levels after 25
days (E) (sample location Fig. 1A., black dashes þ red dot). BDNF (pro-/mature) was found to be elevated at near-equal intensity within tissue at the sagittal ﬁssure release site, while
APP did not display any signiﬁcant change after central infusion for 25 days (F). Dashed red lines indicate control group (UNT) baseline for each blot. Fold changes posted inside bars
with signiﬁcant differences between control and treated groups (Table 2). The ordinate of each blot is the arbitrary band intensity for experimental groups divided by the loading
control band intensity, b-actin (b). Data are mean ± SEM; Table 2 for descriptive statistics; n ¼ 6 (AeD); (*p < 0.05).
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14 days post-surgery to allow for any potential VPAePEG conjugate
toxicity to elicit effects before collecting data. Repeated-measures
ANOVA for the EP/OF studies, assessing percent time spent in
speciﬁc region or arms and total distance traveled, showed no
signiﬁcant changes (Fig. 4; Table 1).
4. Discussion
The objectives of this study were to investigate brain tissue
response to an acute injection of VPAePEG conjugate, chronic
VPAePEG conjugate administration in several cerebral locations
and potential behavioral consequences. We observed two different
trends during the acute studies, ﬁrst, that an intracerebralinjection of VPA resulted in an expected majority decrease of pro-
survival phospho-proteins, and second, the VPAePEG conjugate
resulted in a broad increase in these markers over the time course
(Fig. 2). Another notable difference was in the change of speciﬁc
protein distributions at the injection site through the hour (pro-
tein localization via trafﬁcking; Fig. 3). For the chronic studies,
VPAePEG conjugate dispensed within the sagittal ﬁssure dis-
played a signiﬁcant increase in pro- and mature BDNF versus the
other implant locations (Fig. 3). There was a lack of behavioral
changes in the EP/OF paradigms that suggested that at the loca-
tions tested and for the two tests performed, continuous central
administration at the three sites had no overt behavioral effects on
anxiety nor was there evidence of sedation or behavioral activa-
tion (Fig. 4).
Fig. 4. Behavioral effects of VPAePEG conjugate administration. Male Sprague Dawley rats were implanted with an osmotic minipump delivering VPAePEG conjugate into the
anterior sagittal ﬁssure (S), right lateral ventricle (V) or caudate putamen (C). In the elevated plus and open ﬁeld maze, there were no signiﬁcant differences observed in distance
traveled over the 5 min of testing, suggesting that VPAePEG conjugate did not cause sedation in these animals, nor was there any signiﬁcant effect on anxiety. Data are mean ± SEM;
n ¼ 6; Table 1; infused intracerebroventricularly with phosphate buffered saline (PBS; U).
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displayed signiﬁcant decreases in many of the assayed phospho-
proteins for both time points, contrasting to previously demon-
strated VPA-induced increases in cell culture, chronic oral admin-
istration and chronic ICV administration (1). This observation was
expected within our study upon administration of an acute injec-
tion of unmodiﬁed VPA, since it has been known to undergo
signiﬁcantly rapid clearance from the cerebral compartment within
several minutes, resulting in non-therapeutic levels for both the
cerebral and peripheral blood compartments (15,17). The previous
cell culture and chronic administration reports were employing
VPA administration parameters where the drugwas either conﬁned
to an inescapable culture well compartment or chronically satu-
rating the target compartment with drug, contrasting from our
approach (1).
Puncture injury from the injection needle is a form of traumatic
brain injury and was performed in acute experiments during
administration of drug solutions within whole brain tissue (Fig. 1A)
(24e27). The acute puncture injury was not mitigated due to the
lack of VPA retention at the lesion site, which, without a sufﬁcient
concentration to elicit signaling events, resulted in the poor
outcome. Noshita et al (28,29) noted that the severity of trauma at
the injury interface in non-treated samples can display dramati-
cally decreased pAktSer473 after 1 h, which agrees with our results
displaying a poor outcome (Fig. 2). Our biopsy sampling method
allowed us to trace the lesion pathway for collection of whole brain
tissue and assay for the known pAktSer473 decrease, which
conﬁrmed the severe brain injury (Fig. 1A) (28,29). VPAePEG con-
jugate (2.3 kDa) had the advantage of being able to remain at the
injury interface at an appropriate concentration due to a decreased
propensity for removal, otherwise it would have exhibited the
pooreoutcome proﬁle seen in the control VPA injections (Fig. 2;
Fig. 3). Franke et al (30) reported that a brain stab injury, without
injecting solution, can result in a signiﬁcant increase in pAktSer473
after 2 h (~1.9 fold max increase) and pErk1/2Thr202/Tyr204 after 4 h(~2.1 fold max increase), both later events than our 1 h time point,
suggesting VPAePEG conjugate could induce an expedited pro-
survival response within brain tissue once intracerebrally admin-
istered (4.9 fold increase pAktSer473 and 2.8 fold increase pErk1/
2Thr202/Tyr204 at 1 h). Recently, Zhang et al (31) showed that VPA
exposure was required for an elevation in pErk1/2Thr202/Tyr204 and
pAktSer473 to be present 24 h after a traumatic brain injury event.
Overall, our study helps to highlight the importance of centrally
infusing a molecule which displays the capacity for appropriate
tissue penetration/retention, while maintaining the ability to
effectively elicit therapeutic signaling events.
The phospho-proteins in our study were assayed in an attempt
to gain further insight as to how signaling proteins, running
through Akt and Erk, were responding to the experimental
administration of both drug conﬁgurations (Fig. 1B). As mentioned
above, we sampled the whole needle pathway to obtain severely
damaged brain tissue displaying decreased pAktSer473 and such a
decline in phospho-form has been reported to impact several
downstream targets, which agree with our results (pGSK3bSer9,
CREBSer133, p-mTORSer2448, pFOXO1Ser256/Thr24; Fig. 2A,B1)
(28,29,32e35). Even though PI3K and PDK1 increased in VPAePEG
conjugate samples, pAktThr308 did not display any signiﬁcant
response, suggesting our conditions were similar towhat Yung et al
(36) observed, whereas endoplasmic reticulum (ER) stress from the
acute injection suppressed phosphorylation of the Thr308 site
while still allowing the Ser473 phospho-form to increase
(Supplemental Fig. 1). pAktSer473 has been shown to increase in
neural SH-SY5Y cells exposed to VPA and some of the possible
upstream kinases, normally represented as PDK2, are mTORC2 and
MAPKAPK-2 (37e39). Since phosphorylation of Thr308 and Ser473
are both required for complete activation of Akt, our data suggest
the fully activated form is present when whole brain tissue is
exposed to VPAePEG conjugate, and declining in unmodiﬁed VPA
samples (pAktSer473 drop) (40e42). pBADSer136 is a downstream
phospho-form regulated by Akt activity, and our studies displayed
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while the VPAePEG conjugate samples remained at baseline during
the hour time course (Fig. 2B2).
Uryu et al. (43) reported that patients who died from TBI had
accumulated signiﬁcant levels of amyloid precursor protein (APP)
at the sites of damage. In our current studies, the acute injection of
VPAePEG conjugate resulted in APP returning to baseline by
60 min, whereas the unconjugated VPA samples maintained an
elevated level over the hour (Fig. 3A). BDNF (pro-/mature) and GAP-
43 display a signiﬁcant redistribution to the injection site in un-
conjugated VPA samples, which may be in response to the
decreasing phosphorylation status of many survival proteins,
leading to a larger demand for speciﬁc mitigating and restructuring
agents (Fig. 3B, C). GAP-43 has been reported to localize rapidly at
high concentrations within an hour during axon sprouting, which
our results suggest it also occurs after a penetration injury (Fig. 3C)
(44,45). BDNF-loaded vesicles have also been reported to display
rapid movement within neurons (46). BDNF and GAP-43 are sug-
gested to have direct interactions between each other, during sit-
uations that require the regenerative effects seen with BDNF,
allowing for the promotion of reorganization needed following
injury (47). Brain tissue possessing an enhanced pro-survival
phospho-protein proﬁle, like that seen in the VPAePEG conjugate
samples, could lower demand for neurotrophic protein migration
(BDNF, GAP-43) to the damaged site, potentially mitigating the
entangled protein masses seen within swollen axons after a TBI
event (43). Furthermore, while there were many phospho-protein
decreases seen in the VPA samples, phospho-c-Jun (roles in stress
response and axon regeneration) had signiﬁcantly increased versus
no signiﬁcant response in the VPAePEG conjugate samples (Fig. 3D)
(48).
Our results from chronic central administration of VPAePEG
conjugate did not display any signiﬁcant elevation in APP, while
pro- and mature BDNF were found increased to near-equal in-
tensity within tissue at the sagittal ﬁssure release site (Fig. 3F).
Chronic data for BDNF within caudate putamen tissue may reﬂect a
point source concentration issue that restricted molecule move-
ment and any small change was washed out once the tissue was
homogenized after biopsy. The lateral ventricle release site could
have diluted the VPAePEG conjugate solution to an ineffective
concentration, or any change was potentially washed out after
tissue homogenization as well. The increase of both pro- and
mature BDNF within tissue at the sagittal ﬁssure release site sug-
gests this location may allow for VPAePEG conjugate to maintain
an effective concentration as it acts upon the largely accessible
tissue adjacent to the cannula needle, all while not penetrating
brain tissue (Fig. 3F). Brain tissue taken posterior to all three release
sites did not showany increase in BDNF, indicating drug penetrance
was not achieved within our current experimental administration
parameters (Fig. 3E).
To conclude, in a whole animal system, we have shown an
intracerebral injection of the VPAePEG conjugate increased virtu-
ally all assayed phospho-proteins, several of which are known pro-
survival biomarkers. The decreased phospho-protein proﬁle for
unmodiﬁed VPA suggests that trauma from intracerebral injection
was not mitigated due to the known rapid clearance. Chronic
release of VPAePEG conjugate in the sagittal ﬁssure displayed a
signiﬁcant elevation of pro- and mature BDNF, suggesting this
location could be an optimal release site for future experiments
with ﬂow-rates/concentrations of drug to achieve greater cerebro-
global penetrance. Also, rats receiving centrally infused VPAePEG
conjugate at three different intracerebral cannula locations did not
display any signiﬁcant alterations to behavior. These data suggest
that VPAePEG conjugatemay exhibit an enhanced property to elicit
pro-survival signaling at the injection site tested within this study,while not overtly altering behavior during chronic central
administration.
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